Table 1

Demographic data from all patients participating in the study.

Case

Age (years)

Sex

Subtype (DSM-IV)

Duration of illness (years)

Antipsychotic treatment, dosage


1

56

M

Schizophrenia, undifferentiated

9

Risperdal consta 25 mg/2w

2

23

F

Schizophrenia, undifferentiated

3

Leponex 700 mg/day,

3

29

M

Schizophrenia, unspecified

8

Risperdal 2 mg/day, Abilify 25 mg/day

4

45

M

Schizophrenia, paranoid

6

NA

5

35

M

Schizophrenia, unspecified

11

Leponex 200 mg/day, Abilify 15 mg/day

6

54

M

Schizophrenia, undifferentiated

29

Zyprexa 15 mg/day

7

51

M

Schizophrenia, paranoid

23

Leponex 100 mg/day, Abilify 10 mg/day

8

56

M

Schizophrenia, undifferentiated

> 15

Zyprexa 10 mg/day, Cisordinol 140 mg inj 1/4w

9

-

-

-

-

-

10

39

F

Schizophrenia, paranoid

8

Risperdal 4 mg/day

11

44

M

Schizophrenia, unspecified

26

Leponex 800 mg/day, Abilify 10 mg/day


Case 9 dropped out due to difficulties ingesting the study medicine.

Wass et al. BMC Medicine 2011 9:40   doi:10.1186/1741-7015-9-40

Open Data